Form 8-K - Current report:
SEC Accession No. 0001213900-25-050329
Filing Date
2025-06-03
Accepted
2025-06-03 08:00:07
Documents
15
Period of Report
2025-05-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0244428-8k_estrella.htm   iXBRL 8-K 36412
2 FORM OF SECURITIES PURCHASE AGREEMENT DATED AS OF MAY 30, 2025, BY AND BETWEEN E ea024442801ex10-1_estrella.htm EX-10.1 125542
3 PRESS RELEASE DATED AS OF JUNE 3, 2025 ea024442801ex99-1_estrella.htm EX-99.1 12417
  Complete submission text file 0001213900-25-050329.txt   426424

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE esla-20250530.xsd EX-101.SCH 3862
5 XBRL DEFINITION FILE esla-20250530_def.xml EX-101.DEF 26752
6 XBRL LABEL FILE esla-20250530_lab.xml EX-101.LAB 36957
7 XBRL PRESENTATION FILE esla-20250530_pre.xml EX-101.PRE 25376
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0244428-8k_estrella_htm.xml XML 6083
Mailing Address 5858 HORTON STREET, SUITE 370 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET, SUITE 370 EMERYVILLE CA 94608 (510) 318-9098
Estrella Immunopharma, Inc. (Filer) CIK: 0001844417 (see all company filings)

EIN.: 861314502 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40608 | Film No.: 251017189
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)